The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

PLXDC1  -  plexin domain containing 1

Homo sapiens

Synonyms: Plexin domain-containing protein 1, TEM3, TEM7, Tumor endothelial marker 3, Tumor endothelial marker 7
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PLXDC1


High impact information on PLXDC1

  • Here, we identify several new variants of TEM7, derived by alternative splicing, that are predicted to be intracellular (TEM7-I), secreted (TEM7-S), or on the cell surface membrane (TEM7-M) of tumor endothelium [6].
  • Tumor endothelial marker 7 (TEM7) was recently identified as an mRNA transcript overexpressed in the blood vessels of human solid tumors [6].
  • Overexpression of Txnip by infecting melanoma cells with adenovirus increased TEM 3-fold vs. control (P < 0.001), and this increase was blocked by N-acetylcysteine, indicating a redox-sensitive mechanism [7].
  • A clonal strain was found for TEM-24- but also for TEM-3- and TEM-1- or 2-producing isolates [8].
  • This new enzyme, which has a pI of 6.28, is derived from TEM-3 and has a single amino acid substitution also encountered in TEM-59 (inhibitor-resistant TEM beta-lactamase IRT-17): Ser-130 to Gly [9].

Chemical compound and disease context of PLXDC1


Biological context of PLXDC1


Anatomical context of PLXDC1


Associations of PLXDC1 with chemical compounds

  • When the higher inoculum was used, MICs of at least one antimicrobial agent increased at least fourfold in strains producing TEM-3, TEM-10, TEM-28, TEM-43, SHV-5, SHV-18, and K1 [18].
  • TEM-20 differed from TEM-19 by a silent mutation at position 925 (A for G), and TEM-21 differed from TEM-3 and TEM-14 by a single mutation (G for A) in an unreported position 660. beta-lactamase conferring low resistance to ceftazidime (TEM-29), was described [19].
  • Clavulanate and penam sulphones (sulbactam and tazobactam) were more active against TEM-1 and OXA-1, but were less active against TEM-3 and cephalosporinase (Case) than SYN-1012 [20].
  • Plasmid-mediated beta-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam [3].
  • The cefotaxime-related compounds Ro 25-0534 and Ro 23-9424 were hydrolyzed to any significant extent only by the TEM-3 enzyme (relative catalytic efficiencies, 1.2 and 4.7, respectively [21].

Other interactions of PLXDC1

  • A TEM-2 derivative, TEM-201, with characteristics similar to those of TEM-7 was selected spontaneously in the presence of ceftazidime in vitro [3].
  • When the bacteria were screened for ESBL production and the lower inoculum was used, several strains with ESBLs, including CTX-M-10, TEM-3, TEM-10, TEM-12, TEM-6, SHV-18, and K1, gave false-negative results for one or more antimicrobial agents (MICs below the NCCLS screening concentration for detecting suspected ESBLs) [18].
  • Immunohistochemistry with an antibody for PLXDC1 showed protein expression in GBM microvasculature, but not in the normal brain endothelium tested [22].
  • Except for TEM-10 for which the IC50s of the two antibiotics were the same, imipenem showed significantly greater activity than latamoxef against TEM-3 and TEM-5 [23].
  • Moderate resistance to cefetamet is observed only in strains producing either the TEM-3 or the TEM-4 enzyme, whereas the prevalence of the other enzymes is of no consequence for the activity of cefetamet [13].

Analytical, diagnostic and therapeutic context of PLXDC1

  • Isoelectric focusing evidenced beta-lactamase activity, with a chromosomal penicillinase (pl 7.7), and one or two additional enzymes with pls ranging from 5.4 to 8.2 identified as presumed TEM-1 pl 5.4, TEM-3 pl 6.3, TEM-24 pl 6.5, SHV-3 pl 7.0, SHV-4 pl 7.8, SHV-5 pl 8.2, or other unidentified beta-lactamases [24].
  • The full-length TEM7 was found inside and membrane part of cells as demonstrated by confocal microscopy [17].
  • A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase [25].


  1. Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes. Sougakoff, W., Goussard, S., Gerbaud, G., Courvalin, P. Rev. Infect. Dis. (1988) [Pubmed]
  2. In vitro activity of an oxycephem OCP 9-176 compared with its sulfur analog and other beta-lactams. Gu, J.W., Chin, N.X., Neu, H.C. Diagn. Microbiol. Infect. Dis. (1991) [Pubmed]
  3. Plasmid-mediated beta-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam. Gutmann, L., Kitzis, M.D., Billot-Klein, D., Goldstein, F., Tran Van Nhieu, G., Lu, T., Carlet, J., Collatz, E., Williamson, R. Rev. Infect. Dis. (1988) [Pubmed]
  4. In vitro activity and beta-lactamase stability of GR69153, a new long-acting cephalosporin. Chin, N.X., Gu, J.W., Fang, W., Neu, H.C. Antimicrob. Agents Chemother. (1991) [Pubmed]
  5. In vitro activity of ME1228, a new parenteral cephalosporin. Neu, H.C., Saha, G., Chin, N.X. Antimicrob. Agents Chemother. (1989) [Pubmed]
  6. Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R. Nanda, A., Buckhaults, P., Seaman, S., Agrawal, N., Boutin, P., Shankara, S., Nacht, M., Teicher, B., Stampfl, J., Singh, S., Vogelstein, B., Kinzler, K.W., St Croix, B. Cancer Res. (2004) [Pubmed]
  7. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Cheng, G.C., Schulze, P.C., Lee, R.T., Sylvan, J., Zetter, B.R., Huang, H. Exp. Cell Res. (2004) [Pubmed]
  8. TEM derivative-producing Enterobacter aerogenes strains: dissemination of a prevalent clone. Dumarche, P., De Champs, C., Sirot, D., Chanal, C., Bonnet, R., Sirot, J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  9. TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3. Neuwirth, C., Madec, S., Siebor, E., Pechinot, A., Duez, J.M., Pruneaux, M., Fouchereau-Peron, M., Kazmierczak, A., Labia, R. Antimicrob. Agents Chemother. (2001) [Pubmed]
  10. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. Pangon, B., Bizet, C., Buré, A., Pichon, F., Philippon, A., Regnier, B., Gutmann, L. J. Infect. Dis. (1989) [Pubmed]
  11. In vitro activity of cefcanel versus other oral cephalosporins. Chin, N.X., Gu, J.W., Neu, H.C. Eur. J. Clin. Microbiol. Infect. Dis. (1991) [Pubmed]
  12. In vitro activity of a catechol-substituted cephalosporin, GR69153. Wise, R., Andrews, J.M., Ashby, J.P., Thornber, D. Antimicrob. Agents Chemother. (1991) [Pubmed]
  13. The threat of resistance to the new oral cephalosporins. Cullmann, W. Chemotherapy. (1992) [Pubmed]
  14. Expression of tumor endothelial marker 7 mRNA and protein in the dorsal root ganglion neurons of the rat. Lee, H.K., Kang, D.S., Seo, I.A., Choi, E.J., Park, H.T., Park, J.I. Neurosci. Lett. (2006) [Pubmed]
  15. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Bauernfeind, A., Grimm, H., Schweighart, S. Infection (1990) [Pubmed]
  16. Identification of the basement membrane protein nidogen as a candidate ligand for tumor endothelial marker 7 in vitro and in vivo. Lee, H.K., Seo, I.A., Park, H.K., Park, H.T. FEBS Lett. (2006) [Pubmed]
  17. Cloning, characterization and neuronal expression profiles of tumor endothelial marker 7 in the rat brain. Lee, H.K., Bae, H.R., Park, H.K., Seo, I.A., Lee, E.Y., Suh, D.J., Park, H.T. Brain Res. Mol. Brain Res. (2005) [Pubmed]
  18. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. Queenan, A.M., Foleno, B., Gownley, C., Wira, E., Bush, K. J. Clin. Microbiol. (2004) [Pubmed]
  19. Molecular characterisation by PCR-restriction fragment length polymorphism of TEM beta-lactamases. Arlet, G., Brami, G., Décrè, D., Flippo, A., Gaillot, O., Lagrange, P.H., Philippon, A. FEMS Microbiol. Lett. (1995) [Pubmed]
  20. SYN-1012: a new beta-lactamase inhibitor of penem skeleton. Phillips, O.A., Czajkowski, D.P., Spevak, P., Singh, M.P., Hanehara-Kunugita, C., Hyodo, A., Micetich, R.G., Maiti, S.N. J. Antibiot. (1997) [Pubmed]
  21. beta-Lactamase hydrolysis of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines. Georgopapadakou, N.H., McCaffrey, C. Antimicrob. Agents Chemother. (1994) [Pubmed]
  22. PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. Beaty, R.M., Edwards, J.B., Boon, K., Siu, I.M., Conway, J.E., Riggins, G.J. J. Neurooncol. (2007) [Pubmed]
  23. In-vitro evaluation of beta-lactamase inhibition by latamoxef and imipenem. Sotto, A., Brunschwig, C., O'Callaghan, D., Ramuz, M., Jourdan, J. J. Antimicrob. Chemother. (1996) [Pubmed]
  24. A seven-year survey of Klebsiella pneumoniae producing TEM-24 extended-spectrum beta-lactamase in Nice University Hospital (1994-2000). Giraud-Morin, C., Fosse, T. J. Hosp. Infect. (2003) [Pubmed]
  25. A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. De Champs, C., Rouby, D., Guelon, D., Sirot, J., Sirot, D., Beytout, D., Gourgand, J.M. J. Hosp. Infect. (1991) [Pubmed]
WikiGenes - Universities